Friday, August 28, 2015 12:10:33 PM
The fact that the EbolaCide glycoprotein has a glycan cap that needs to be removed inside the endosome to attach to the NPC-1 receptor is not related to the prediction of the non-symmetric shape of the virus being a problem. Even if the virus was spherical, the fact that there are glycan caps on the glycoprotein and that the virus causes shedding of soluble glycoprotein (chaff or decoy proteins) are the difficult problems, IMO. My concern about the non-symmetric shape of Ebola was that it might be more difficult for the cides to envelope and destroy the virus once the attachments have been made (viral protein binds to viricide ligand). It didn't have to do with not being able to attach due to the shape of the virus. That part shouldn't matter, IMO.
I maintain that the prediction was not accurate, but neither of us knows how much detail they got in understanding the mechanisms of action / partial efficacy / failure of EbolaCide2 in cell culture testing at USAMRIID.
Best of luck to you in your investments. Time will tell if those that speculate NNVC will fail are correct or if those who speculate NNVC will succeed will be correct. In the mean time, we will all continue to speculate and discuss NNVC pro and con, trying to arrive at the truth.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM